共 50 条
- [41] Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk CategoryMETABOLIC SYNDROME AND RELATED DISORDERS, 2009, 7 (06) : 601 - 610Polis, Adam B.Abate, NicolaCatapano, Alberico L.Ballantyne, Christie M.Davidson, Michael H.Smugar, Steven S.Tershakovec, Andrew M.
- [42] Persistent Dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events – Results of the dyslipidemia international study (DYSIS)Persistente Dyslipidämie in Österreich bei Patienten, die zur Primär- und Sekundärprävention atherosklerotischer Ereignisse mit Statinen behandelt waren – Ergebnisse der Dyslipidemia International Study (DYSIS)Wiener klinische Wochenschrift, 2011, 123 (19-20) : 611 - 617Heinz DrexelFrancois ChazelleChristiane FauerDominik LautschAnselm K Gitt
- [43] Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter studyLIPIDS IN HEALTH AND DISEASE, 2012, 11Ling, Paul Kah HingCiveira, FernandoDan, Andrei GheorgheHanson, Mary E.Massaad, RachidDe Tilleghem, Celine Le BaillyMilardo, ChristopherTriscari, Joseph
- [44] Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter studyLipids in Health and Disease, 11Paul Kah Hing LingFernando CiveiraAndrei Gheorghe DanMary E HansonRachid MassaadCeline Le Bailly De TilleghemChristopher MilardoJoseph Triscari
- [45] Reduzieren Statine das Rezidivrisiko für arterielle Lungenembolien oder tiefe Beinvenenthrombosen?Ist der Einsatz zur Sekundärprävention sinnvoll?Do statins reduce the risk of recurrence for arterial lung embolisms or deep leg vein thrombosis?Does the use of secondary prevention make sense?Der Kardiologe, 2017, 11 (6): : 450 - 451E. Lindhoff-LastB. Haberichter
- [46] EZETIMIBE/SIMVASTATIN 10/40MG VERSUS ATORVASTATIN 40MG IN HIGH CARDIOVASCULAR RISK PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDYATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 21 - 21Civeira, F.Dan, A. G.Hing, P. L. K.Hanson, M. E.Massaad, R.Milardo, C.Triscari, J.
- [48] Mediterrane oder fettarme Ernährung zur Sekundärprävention bei koronarer Herzkrankheit?Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet 2022; 399: 1876–1885 (Randomisiert-kontrollierte Studie)Zeitschrift für Allgemeinmedizin, 2022, 98 (12): : 413 - 414Natalie MartyPeter Kleist
- [49] A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient RegistryARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4893 - 4896Camacho, Alma AveytiaGullapelli, RakeshPhilip, VineethaDaliri, SoudabehMemon, RubaDiGregorio, HeleneKaram, Lily RomeroMonga, KanikaAvenatti, EleonoraNasir, KhurramGuevara, Myriam
- [50] Pharmakoökonomische Bewertung von Pravastatin in der Sekundärprävention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen CholesterinwertenEine Analyse für Deutschland auf der Grundlage der CARE-StudiePharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for germany based on the CARE studyHerz, 1998, 23 (5) : 319 - 329Thomas D. SzucsGeorg GuggenbergerKarin BergerWinfried MärzJürgen R. Schäfer